Evidence map›Paper›PMID 39737899›Full record

ArticleNature communications2024

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.

Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, Usama S Gergis, Martin E Guiterrez, Ran Reshef, Sumit K Subudhi, Céline F Jacquemont, Joseph H Senesac, J Henri Bayle and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02744287 (A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02744287 phase1terminatednot on this map

A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2016 to 2023Enrolled52ConditionsMetastatic Castration-resistant Prostate Cancer, Metastatic Prostate CancerArmsBPX-601, Rimiducid
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mark N Stein *Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Ecaterina E Dumbrava *The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eeileana@mdanderson.org.ORCID 0000-0002-1959-0536
Benjamin A TeplyUniversity of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-7366-6212
Usama S GergisThomas Jefferson University, Philadelphia, PA, USA.
Martin E GuiterrezHackensack University Medical Center, Hackensack, NJ, USA.ORCID 0000-0003-3156-3159
Ran ReshefHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-2185-9546
Sumit K SubudhiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5208-7732
Céline F JacquemontBellicum Pharmaceuticals, Inc., Houston, TX, USA.
Joseph H SenesacBellicum Pharmaceuticals, Inc., Houston, TX, USA.
J Henri BayleBellicum Pharmaceuticals, Inc., Houston, TX, USA.ORCID 0000-0002-9829-2499
Charity D ScriptureBellicum Pharmaceuticals, Inc., Houston, TX, USA.
Monica S ChatwalH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Mehmet A BilenDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Walter M StadlerUniversity of Chicago, Chicago, IL, USA.
Carlos R BecerraBaylor University Medical Center, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid. Thirty-three patients received BPX-601 with or without rimiducid, 24 patients with mPDAC and 9 with mCRPC. Two dose-limiting toxicities and two treatment-related deaths occurred in the highest-dose mCRPC cohort, after which the study was terminated, without determination of the RP2D. Two mCRPC patients experienced partial responses (one unconfirmed), and 56% of mCRPC patients achieved ≥50% reduction in prostate-specific antigen. BPX-601 cell expansion, long-term persistence in peripheral blood, and tumor infiltration were observed. Rimiducid increased circulating inflammatory cytokines/chemokines consistent with GoCAR-T® cell activation. These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.

Indexed as

Antigens, NeoplasmGPI-Linked ProteinsNeoplasm ProteinsPancreatic NeoplasmsAgedCD40 AntigensFemaleHumansImmunotherapy, AdoptiveMaleMiddle AgedMyeloid Differentiation Factor 88Neoplasm MetastasisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, Chimeric AntigenAntigens, NeoplasmCD40 AntigensGPI-Linked ProteinsMyeloid Differentiation Factor 88Neoplasm ProteinsPSCA protein, humanReceptors, Chimeric Antigen

Identifiers

PMID39737899
PMCPMC11685978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.